CJT-L31

CJT-L31 is an undisclosed biologic biosimilar candidate being developed by Crossject for use in emergency or crisis medical situations. The product utilizes Crossject's proprietary ZENEO® needle-free autoinjector technology, which is designed to provide rapid and reliable drug delivery without the use of a needle. CJT-L31 is being advanced through the 351(k) regulatory pathway in the United States, confirming its status as a biosimilar or interchangeable biological product. While the specific reference biologic and primary therapeutic indication have not been publicly disclosed, the drug is part of a broader portfolio of emergency treatments. Crossject has projected a target launch date for CJT-L31 in 2031.